Skip to main navigation Skip to search Skip to main content

Exploring Heterogeneity in the Cost-Effectiveness of High-Flow Nasal Cannula Therapy in Acutely Ill Children—Insights From the Step-Up First-line Support for Assistance in Breathing in Children Trial Using a Machine Learning Method

  • Zaid Hattab
  • , Silvia Moler-Zapata
  • , Edel Doherty
  • , Zia Sadique
  • , Padmanabhan Ramnarayan
  • , Stephen O'Neill
  • University of Galway
  • An-Najah University
  • London School of Hygiene and Tropical Medicine
  • Imperial College London
  • UCL Institute of Child Health and Great Ormond Street Hospital for Children NHS Foundation Trust

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

2 Citations (Scopus)

Abstract

Objectives: To investigate heterogeneity in the cost-effectiveness of high-flow nasal cannula (HFNC) therapy compared with continuous positive airway pressure (CPAP) for acutely ill children requiring noninvasive respiratory support. Methods: Using data from the First-line Support for Assistance in Breathing in Children trial, we explore heterogeneity at the patient and subgroup levels using 2 causal forest approaches and a seemingly unrelated regression approach for comparison. First-line Support for Assistance in Breathing in Children is a noninferiority randomized controlled trial (ISRCTN60048867) involving 24 UK pediatric intensive care units. The Step-up trial focuses on acutely ill children aged 0 to 15 years, requiring noninvasive respiratory support. A total of 600 children were randomly assigned to HFNC and CPAP groups in a 1:1 allocation ratio, with 94 patients excluded because of data unavailability. Results: The primary outcome is the incremental net monetary benefit (INB) of HFNC compared with CPAP, using a willingness-to-pay threshold of £20 000 per quality-adjusted life year gain. INB is derived from total costs and quality-adjusted life years at 6 months. Subgroup analysis showed that some subgroups, such as male children, those aged less than 12 months, and those without severe respiratory distress at randomization, had more favorable INB results. Patient-level analysis revealed heterogeneity in INB estimates, particularly driven by the cost component, with greater uncertainty for those with higher INBs. Conclusions: The estimated overall INB of HFNC is significantly larger for specific patient subgroups, suggesting that the cost-effectiveness of HFNC can be heterogeneous, which highlights the importance of considering patient characteristics in evaluating the cost-effectiveness of HFNC.

Original languageEnglish
Pages (from-to)60-69
Number of pages10
JournalValue in Health
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 2025

Keywords

  • causal forest
  • cost-effectiveness
  • heterogeneous effects
  • machine learning

Fingerprint

Dive into the research topics of 'Exploring Heterogeneity in the Cost-Effectiveness of High-Flow Nasal Cannula Therapy in Acutely Ill Children—Insights From the Step-Up First-line Support for Assistance in Breathing in Children Trial Using a Machine Learning Method'. Together they form a unique fingerprint.

Cite this